AngioSoma, Inc. (OTC Pink: SOAN) Surges 162% After Announcing Acquisition of Diabetes Relief LLC

Spotlight Growth - Penny Stocks, Small Cap Stocks, Micro-Cap and Micro Cap Stocks, Stock Exchange, NASDAQ, Crypto, BitCoin, DogeCoin, Ai, Artificial Intelligence, Chat GPT, OpenAi, Open Ai, ASURE Software, Trending, Now, Breaking News, BioTech, Data, Analytics, Technology, Big Tech, Banking, SVB, Bank Closures, Failures, Finance, Stock Market News, WeBull, RobinHood, Reddit Traders, Trading, Investing, Investors, Investment, Investments, Day Trading, Real Estate, VC, Venture Capital, Private Equity, Firm, Firms, OTC Markets, Public, Private, OTCQB, GOOG, APPLE, Shareholders, Stakeholders, Shares, Finance Education, Blog, Articles, Consumer Goods, Pharma, Commodities, Precious Metals, Gold, Silver, Cannabis, CBD, Lithium, Electric Vehicles, Solar, Tesla, Charging, EV, Cloud Computing, Wall Street Bets, Sports Betting, Economy, Economics, IPO, Trade Ideas, Intellectual Property Rights, Private Placement, Crowd Funding, Fundraising, Meta, Metaverse, Web 3, Cyber, Cybersecurity, Cyber Security, Aircraft, VPN, Yahoo Finance, Benzinga, BarChart.

AngioSoma, Inc. (OTC Pink: SOAN) is a clinical stage biotechnology company, focused on improving the effectiveness of current, standard treatments. Shares jumped 162.22% through early trading on Friday, December 14, 2018. Over the past month, AngioSoma has seen an average daily volume of 432,975 shares. However, already 6.32 million shares or $149,152 in dollar volume, have traded hands through Friday morning.

Shares surged after AngioSoma announced it has entered into a partially-binding LOI with Diabetes Relief LLC, under which AngioSoma will acquire 100% of the equity interests of Diabetes Relief. Clinical trials for the Federal Drug Administration’s (FDA) approval for AngioSoma’s Liprostin™ “may be facilitated by the acquisition.” Diabetes Relief’s patented therapy “treats the root cause of diabetes, instead of just the symptoms, as conventional treatment has done.” Diabetes Relief is expected to earn $2,416,716 in gross revenue for the current year. Here is the full press release detailing the acquisition:

AngioSoma, Inc. Press Release:

Houston, TX, Dec. 14, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — AngioSoma, Inc. (OTC: SOAN) announced today the Company has entered into a partially binding letter of intent to acquire 100% of the equity interests in Diabetes Relief LLC. Diabetes Relief licenses medical facilities for the treatment of metabolic disorder, specializing in diabetes, for the use of patented protocols, processes, and intellectual property. Treatments are individualized to a patient’s condition and metabolic state. Diabetes Relief, through providing thousands of treatments, has seen vast improvements for patients. Clinical trials for FDA approval of Liprostin™, that is intended to treat Peripheral Artery Disease, or PAD, may be facilitated by the acquisition.

Gross revenue of Diabetes Relief for the current year is forecasted to be $2,416,716, for the prior year $1,900,944, and for 2015 was $213,434. Revenue growth is expected to increase substantially.

The following statements are quoted from Diabetes Relief’s patent that was issued May 16, 2017: “[I]t is apparent from the clinical results that the technique has usefulness in treating diabetic implications, including blindness and other ocular manifestations, nerve disease, cardiovascular disease, diabetic nephropathy, and poor wound healing. . . . A need exists for a kit that improves impaired hepatic glucose processing in subjects and produce superior results to those previously obtainable. The present embodiments meet those needs.”

Diabetes Relief’s patented therapy treats the root cause of diabetes, instead of just the symptoms, as conventional treatment has done. Diabetes Relief’s patients improve and they are able to escape the treadmill of treatments that do not work.

ABOUT ANGIOSOMA, INC.

AngioSoma, Inc. (https:// angiosoma.com), a Nevada corporation based in Houston, Texas, is dedicated to improving the mental and physical wellbeing of men and women. To accomplish that purpose, we are launching a line of supplements under our Somaceuticals™ common identity. Our supplements cover three industry segments: nutraceuticals, cosmeceuticals, and pharmaceuticals.

NOTICE REGARDING FORWARD LOOKING STATEMENTS

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.

Article By: Andrew Rego

AngioSoma, Inc. (OTC Pink: SOAN) Surges 162% After Announcing Acquisition of Diabetes Relief LLC

Asure Software (NASDAQ: ASUR) is Expanding to Meet the Rising Demand for Human Capital Management Software

OLB Group (NASDAQ: OLB) and Cuentas (NASDAQ: CUEN) Team Up to Bring Fintech Solutions to Over 32,000 Bodegas Across the United States

New Purchase Orders for SD7 Rugged Device, VK7, and Other Accessories Boost Siyata Mobile’s Outlook (NASDAQ: SYTA)

Telcoin (TEL) Quietly Leads a Crypto Remittance Revolution

Vision Marine (NASDAQ: VMAR): An Innovative, Revenue-Producing Company Riding the Electric Boating Growth Trend

Decentraland (MANA) is the Proof of Concept for the Emerging Metaverse

Alfi, Inc. (NASDAQ: ALF) Climbs 51% After Entering Into Agreement with Miami-Based Fulfillment & Distribution Center For its Ridesharing Digital Tablet Rollout

Telcoin (TEL) Continues to Demonstrate Fundamental Progress, Displaying Bullish Technical Setup

Grove Collaborative (NYSE: GROV) Expands Retail Distribution Footprint Into 2,200 Additional Stores

The Metaverse is Exploding in Popularity and Growth

Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

Safe-T (NASDAQ: SFET) Has Been Selected to Present at the United Nations’ Office of Information and Communications Technology Event

Safe-T Group (NASDAQ: SFET) Reports Fourth Quarter and Full Year 2020 Financial Results

Safe-T Group Ltd. (NASDAQ: SFET) Estimates Record-High Annual Revenues of Approximately $4.9 Million Representing ~50% Growth YoY 2020

Safe-T Group Ltd. (NASDAQ: SFET) to Participate at A.G.P.’s Virtual Emerging Growth Technology Conference on February 4, 2021

Nvidia Announces New Chip Specifically For Ethereum Mining

Sortis Holdings, Inc. (OTC Pink: SOHI) Announces Results for Second Quarter 2020

Medical Marijuana Coming Soon to Virginia

SushiSwap (SUSHI) Appropriates Uniswap’s Liquidity Pool by Preempting Native Token Release

Europe Shows Signs of Warming to SPACs

Understanding EBITDA and Adjusted EBITDA: A View Into Asure’s (NASDAQ: ASUR) Recent Financial Performance

From Microsoft to Travel Tech: VCI Global’s (NASDAQ: VCIG) Expanding AI Horizons

Singapore’s Leap into the Future of Cell and Gene Therapies

Asure (NASDAQ: ASUR) Completes Capital Raise to Fuel High-Interest Debt Reduction, Craig-Hallum Analyst Praises Move and Estimates Bullish Outcome

Asure (NASDAQ: ASUR) Reports Massive 50% Y/Y Revenue Growth During Q2 2023, Raises $40 Million to Pay Off High-Interest Debt and Fund Acquisitions

Hanryu Holdings (NASDAQ: HRYU) Introduces AI-powered Assistant, Deok Gom, to Boost Engagement on FANTOO Platform

Tilray (NASDAQ: TLRY) Acquires Major Beer Brands, Poised to Become 5th Largest Craft Beer Brewer in the United States

Asure Software’s (NASDAQ: ASUR) Q2 2023 Financial Results Indicate Robust Growth in HCM Market, Solidifies Strategic Partnership with Vestwell

Campbell Soup Company (NYSE: CPB) Acquires Pasta Sauce Parent Company, Sovos Brands (NASDAQ: SOVO), in a Deal Valued at $2.7 Billion

ParaZero Technologies (NASDAQ: PRZO) Secures Repeat Order for Bespoke Drone Safety System from a Fortune 500 Automotive Manufacturer

Recent News

Understanding EBITDA and Adjusted EBITDA: A View Into Asure’s (NASDAQ: ASUR) Recent Financial Performance

From Microsoft to Travel Tech: VCI Global’s (NASDAQ: VCIG) Expanding AI Horizons

Categories

Site Navigation